Direct Answer
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) examined in a small number of human and animal studies. It is a research chemical and is not an approved therapeutic. As of June 2026 it sits in a regulatory gray zone: CJC-1295 was removed from the FDA 503A Category 2 bulk-substances list in April 2026 but not added to Category 1, and it remains not FDA-approved.
Summary Table
Evidence Level
Low
Key Information
Classification
Key Takeaways
- CJC-1295 is a long-acting GHRH analog studied in early human and animal research
- Reported effects are on growth-hormone and IGF-1 levels, not long-term outcomes
- It is a research chemical not approved for human use
Scientific Overview
In Plain English
CJC-1295 is a lab-made version of a hormone (GHRH) that signals the pituitary to release growth hormone. A small early human study and animal research examined its effects on growth-hormone levels. It is not an approved medicine and is sold as a research chemical.
Scientific Details
CJC-1295 is a long-acting GHRH analog. An early study in healthy adults reported prolonged increases in growth hormone and insulin-like growth factor 1 (IGF-1), and animal work examined growth normalization in GHRH-deficient models. Human evidence beyond hormone levels is limited, and it is not an approved drug.
How It Works
CJC-1295 is described in research as a long-acting GHRH analog; studies associate it with prolonged stimulation of growth-hormone and IGF-1 secretion.
Mechanism of Action
GHRH receptor agonism
human
Research associates CJC-1295 with extended stimulation of growth-hormone and IGF-1 release.
Evidence Level
Human Evidence
An early study in healthy adults reported prolonged growth-hormone and IGF-1 increases.
Animal Evidence
Animal studies examined growth normalization in GHRH-deficient models.
Limitations
Human evidence is limited to small early studies focused on hormone levels rather than long-term outcomes; safety with unregulated use is not established.
Why This Grade
Graded low: human evidence is limited to a small early study of hormone levels (GH/IGF-1) rather than long-term clinical outcomes, supported by animal pharmacology. CJC-1295 is not an approved therapeutic and safety with unregulated use is not established, so the grade reflects early pharmacology rather than controlled outcome data.
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology and Metabolism.Human Studydoi:10.1210/jc.2005-1536 →
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology. Endocrinology and Metabolism.Animal Studydoi:10.1152/ajpendo.00201.2006 →
Alternative Names
- CJC 1295
- GHRH analog
Claim Boundaries
ION BLUE is an educational research aggregator. This content summarizes published scientific literature. It is not medically reviewed, is not medical advice, and is not a recommendation to use any substance. Several peptides discussed are research chemicals not approved for human use. Consult a licensed healthcare provider. This entry does not assert that CJC-1295 is safe or beneficial for any use and is not a recommendation to use it.
This page summarizes published research and is for informational purposes only; it is not medical advice.